1. Home
  2. EIM vs DNA Comparison

EIM vs DNA Comparison

Compare EIM & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Municipal Bond

EIM

Eaton Vance Municipal Bond

HOLD

Current Price

$9.84

Market Cap

513.2M

Sector

Finance

ML Signal

HOLD

Logo Ginkgo Bioworks Holdings Inc.

DNA

Ginkgo Bioworks Holdings Inc.

HOLD

Current Price

$9.34

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIM
DNA
Founded
N/A
2008
Country
United States
United States
Employees
N/A
485
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
513.2M
455.8M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
EIM
DNA
Price
$9.84
$9.34
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
118.4K
1.2M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.41
$5.37
52 Week High
$10.54
$17.58

Technical Indicators

Market Signals
Indicator
EIM
DNA
Relative Strength Index (RSI) 51.78 61.43
Support Level $9.82 $7.34
Resistance Level $10.02 $10.21
Average True Range (ATR) 0.09 0.60
MACD -0.00 0.04
Stochastic Oscillator 65.50 92.90

Price Performance

Historical Comparison
EIM
DNA

About EIM Eaton Vance Municipal Bond

Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Share on Social Networks: